The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective

BACKGROUND: The impact of programmed death receptor-ligand1 (PD-L1) on costs and value of the immune check point inhibitors (ICPI) has received minimal attention. Objectives: 1- Design a sliding scale to grade survival in 2nd-line non-small-cell lung cancer (NSCLC). 2- Compare costs and value of Niv...

Descripción completa

Detalles Bibliográficos
Autor principal: Guirgis, Helmy M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819662/
https://www.ncbi.nlm.nih.gov/pubmed/29463302
http://dx.doi.org/10.1186/s40425-018-0320-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819662/
https://www.ncbi.nlm.nih.gov/pubmed/29463302
http://dx.doi.org/10.1186/s40425-018-0320-3

Ejemplares similares